Ravi K. Amaravadi

40.3k total citations · 11 hit papers
146 papers, 15.6k citations indexed

About

Ravi K. Amaravadi is a scholar working on Molecular Biology, Oncology and Epidemiology. According to data from OpenAlex, Ravi K. Amaravadi has authored 146 papers receiving a total of 15.6k indexed citations (citations by other indexed papers that have themselves been cited), including 83 papers in Molecular Biology, 70 papers in Oncology and 55 papers in Epidemiology. Recurrent topics in Ravi K. Amaravadi's work include Autophagy in Disease and Therapy (54 papers), Melanoma and MAPK Pathways (30 papers) and Cutaneous Melanoma Detection and Management (21 papers). Ravi K. Amaravadi is often cited by papers focused on Autophagy in Disease and Therapy (54 papers), Melanoma and MAPK Pathways (30 papers) and Cutaneous Melanoma Detection and Management (21 papers). Ravi K. Amaravadi collaborates with scholars based in United States, China and Switzerland. Ravi K. Amaravadi's co-authors include Alec C. Kimmelman, Craig B. Thompson, Eileen White, Jayanta Debnath, Rani Ojha, Shengfu Piao, Julian J. Lum, Lynn M. Schuchter, Angelique Onorati and Matheus Dyczynski and has published in prestigious journals such as Cell, Proceedings of the National Academy of Sciences and Journal of Clinical Investigation.

In The Last Decade

Ravi K. Amaravadi

144 papers receiving 15.4k citations

Hit Papers

Autophagy inhibition enhances therapy-induced apoptosis i... 2007 2026 2013 2019 2007 2016 2007 2011 2019 250 500 750
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Autophagy inhibition enhances therapy-induced apoptosis in a Myc-induced model of lymphoma
    2007 936 citations Ravi K. Amaravadi, Julian J. Lum et al. profile →
  2. Tumor Interferon Signaling Regulates a Multigenic Resistance Program to Immune Checkpoint Blockade
    2016 804 citations Alexander C. Huang, Ravi K. Amaravadi et al. profile →
  3. Systemic Treatment with the Antidiabetic Drug Metformin Selectively Impairs p53-Deficient Tumor Cell Growth
    2007 756 citations Monica Buzzai, Russell G. Jones et al. Cancer Research profile →
  4. Principles and Current Strategies for Targeting Autophagy for Cancer Treatment
    2011 728 citations Ravi K. Amaravadi, Michael T. Lotze et al. Clinical Cancer Research profile →
  5. Targeting Autophagy in Cancer: Recent Advances and Future Directions
    2019 695 citations Ravi K. Amaravadi et al. Cancer Discovery profile →
  6. Targeting autophagy in cancer
    2018 649 citations Angelique Onorati, Ravi K. Amaravadi et al. profile →
  7. Recent insights into the function of autophagy in cancer
    2016 648 citations Ravi K. Amaravadi et al. profile →
  8. Developmental Relationships of Four Exhausted CD8+ T Cell Subsets Reveals Underlying Transcriptional and Epigenetic Landscape Control Mechanisms
    2020 598 citations Wei Xu, Ravi K. Amaravadi et al. profile →
  9. Enhancing CD8+ T Cell Fatty Acid Catabolism within a Metabolically Challenging Tumor Microenvironment Increases the Efficacy of Melanoma Immunotherapy
    2017 481 citations Xiaowei Xu, Giorgos C. Karakousis et al. profile →
  10. A phase I/II trial of hydroxychloroquine in conjunction with radiation therapy and concurrent and adjuvant temozolomide in patients with newly diagnosed glioblastoma multiforme
    2014 409 citations Yunyoung C Chang, Andrea B. Troxel et al. Autophagy profile →
  11. SIRT1 is downregulated by autophagy in senescence and ageing
    2020 357 citations Ravi K. Amaravadi et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Ravi K. Amaravadi United States 57 8.7k 6.5k 4.4k 2.7k 2.7k 146 15.6k
Kevin M. Ryan United Kingdom 53 7.3k 0.8× 4.3k 0.7× 3.0k 0.7× 2.3k 0.9× 1.2k 0.5× 115 11.8k
Robert S. DiPaola United States 49 5.9k 0.7× 4.0k 0.6× 3.1k 0.7× 3.2k 1.2× 1.1k 0.4× 234 14.2k
Domenico Coppola United States 75 11.7k 1.3× 4.0k 0.6× 9.4k 2.1× 5.0k 1.9× 2.6k 1.0× 367 23.3k
Kapil N. Bhalla United States 87 17.3k 2.0× 1.7k 0.3× 5.9k 1.3× 2.2k 0.8× 2.8k 1.0× 378 26.0k
Charles Dumontet France 69 9.2k 1.0× 1.1k 0.2× 8.6k 2.0× 1.9k 0.7× 1.5k 0.6× 377 20.7k
Hongming Pan China 46 3.8k 0.4× 2.3k 0.4× 3.1k 0.7× 1.8k 0.7× 948 0.4× 222 9.2k
Ashok K. Saluja United States 61 4.3k 0.5× 1.6k 0.3× 3.9k 0.9× 1.0k 0.4× 1.8k 0.7× 243 11.7k
Sergei I. Grivennikov United States 47 8.2k 0.9× 2.6k 0.4× 10.0k 2.3× 4.7k 1.8× 8.6k 3.2× 73 24.3k
Satoru Todo Japan 73 3.9k 0.4× 3.2k 0.5× 2.9k 0.7× 944 0.4× 2.5k 0.9× 570 20.3k
Galina K. Sukhova United States 83 7.3k 0.8× 4.6k 0.7× 3.2k 0.7× 6.6k 2.5× 10.9k 4.1× 168 27.1k

Countries citing papers authored by Ravi K. Amaravadi

Since Specialization
Citations

This map shows the geographic impact of Ravi K. Amaravadi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ravi K. Amaravadi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ravi K. Amaravadi more than expected).

Fields of papers citing papers by Ravi K. Amaravadi

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ravi K. Amaravadi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ravi K. Amaravadi. The network helps show where Ravi K. Amaravadi may publish in the future.

Co-authorship network of co-authors of Ravi K. Amaravadi

This figure shows the co-authorship network connecting the top 25 collaborators of Ravi K. Amaravadi. A scholar is included among the top collaborators of Ravi K. Amaravadi based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ravi K. Amaravadi. Ravi K. Amaravadi is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Crissey, Mary Ann S., Monika Bhardwaj, Vaibhav Jain, et al.. (2024). Divergent effects of acute and chronic PPT1 inhibition in melanoma. Autophagy. 21(2). 394–406. 3 indexed citations
2.
Huang, Alexander C., Xiaowei Xu, Rosemarie Mick, et al.. (2024). FDG PET/CT Imaging 1 Week after a Single Dose of Pembrolizumab Predicts Treatment Response in Patients with Advanced Melanoma. Clinical Cancer Research. 30(9). 1758–1767. 10 indexed citations
3.
Sukumaran, Abitha, Priyanka Arora, Kwangmin Choi, et al.. (2024). A Multimodal Drug–Diet–Immunotherapy Combination Restrains Melanoma Progression and Metastasis. Cancer Research. 84(14). 2333–2351. 2 indexed citations
4.
Hong, Hwanhee, Kevin J. Anstrom, Susan Halabi, et al.. (2023). Safety and efficacy of hydroxychloroquine as prophylactic against COVID-19 in healthcare workers: a meta-analysis of randomised clinical trials. BMJ Open. 13(6). e065305–e065305. 4 indexed citations
5.
Aggarwal, Charu, Joshua Bauml, Tomás S. Alemán, et al.. (2023). A Phase II Open-Label Trial of Binimetinib and Hydroxychloroquine in Patients With Advanced KRAS-Mutant Non-Small Cell Lung Cancer. The Oncologist. 28(7). 644–e564. 13 indexed citations
6.
Jain, Vaibhav, Sandra L. Harper, Dylan Fingerman, et al.. (2022). Targeting UGCG Overcomes Resistance to Lysosomal Autophagy Inhibition. Cancer Discovery. 13(2). 454–473. 18 indexed citations
7.
Anstadt, Emily J., Brian Chu, Nikhil Yegya‐Raman, et al.. (2022). Moderate Colitis Not Requiring Intravenous Steroids Is Associated with Improved Survival in Stage IV Melanoma after Anti-CTLA4 Monotherapy, But Not Combination Therapy. The Oncologist. 27(9). 799–808. 4 indexed citations
8.
Zeh, Herbert J., Nathan Bahary, Brian A. Boone, et al.. (2020). A Randomized Phase II Preoperative Study of Autophagy Inhibition with High-Dose Hydroxychloroquine and Gemcitabine/Nab-Paclitaxel in Pancreatic Cancer Patients. Clinical Cancer Research. 26(13). 3126–3134. 170 indexed citations
9.
Mohiuddin, Jahan J., Brian Chu, Andrea Facciabene, et al.. (2020). Association of Antibiotic Exposure With Survival and Toxicity in Patients With Melanoma Receiving Immunotherapy. JNCI Journal of the National Cancer Institute. 113(2). 162–170. 96 indexed citations
10.
Haas, Naomi B., Leonard J. Appleman, Mark N. Stein, et al.. (2019). Autophagy Inhibition to Augment mTOR Inhibition: a Phase I/II Trial of Everolimus and Hydroxychloroquine in Patients with Previously Treated Renal Cell Carcinoma. Clinical Cancer Research. 25(7). 2080–2087. 112 indexed citations
11.
Sanseviero, Emilio, Erin M. O’Brien, Tamer B. Shabaneh, et al.. (2019). Anti–CTLA-4 Activates Intratumoral NK Cells and Combined with IL15/IL15Rα Complexes Enhances Tumor Control. Cancer Immunology Research. 7(8). 1371–1380. 51 indexed citations
12.
Parekh, Vishwas, Joseph F. Sobanko, Christopher J. Miller, et al.. (2018). NRAS Q61R and BRAF G466A mutations in atypical melanocytic lesions newly arising in advanced melanoma patients treated with vemurafenib. Journal of Cutaneous Pathology. 46(3). 190–194. 4 indexed citations
13.
Budina-Kolomets, Anna, Marie R. Webster, Julia I-Ju Leu, et al.. (2016). HSP70 Inhibition Limits FAK-Dependent Invasion and Enhances the Response to Melanoma Treatment with BRAF Inhibitors. Cancer Research. 76(9). 2720–2730. 34 indexed citations
14.
Amaravadi, Ravi K., Russell J. Schilder, Lainie P. Martin, et al.. (2015). A Phase I Study of the SMAC-Mimetic Birinapant in Adults with Refractory Solid Tumors or Lymphoma. Molecular Cancer Therapeutics. 14(11). 2569–2575. 101 indexed citations
15.
Rangwala, Reshma, Robert D. Leone, Yunyoung C Chang, et al.. (2014). Phase I trial of hydroxychloroquine with dose-intense temozolomide in patients with advanced solid tumors and melanoma. Autophagy. 10(8). 1369–1379. 294 indexed citations
16.
Ascierto, Paolo A., David R. Minor, Antoni Ribas, et al.. (2013). Phase II Trial (BREAK-2) of the BRAF Inhibitor Dabrafenib (GSK2118436) in Patients With Metastatic Melanoma. Journal of Clinical Oncology. 31(26). 3205–3211. 338 indexed citations
17.
Selvakumaran, Muthu, Ravi K. Amaravadi, Irina A. Vasilevskaya, & Peter J. O’Dwyer. (2013). Autophagy Inhibition Sensitizes Colon Cancer Cells to Antiangiogenic and Cytotoxic Therapy. Clinical Cancer Research. 19(11). 2995–3007. 182 indexed citations
18.
Krepler, Clemens, Srinivas K. Chunduru, Molly B. Halloran, et al.. (2013). The Novel SMAC Mimetic Birinapant Exhibits Potent Activity against Human Melanoma Cells. Clinical Cancer Research. 19(7). 1784–1794. 79 indexed citations
19.
Lazova, Rossitza, Robert L. Camp, Vincent Klump, et al.. (2011). Punctate LC3B Expression Is a Common Feature of Solid Tumors and Associated with Proliferation, Metastasis, and Poor Outcome. Clinical Cancer Research. 18(2). 370–379. 260 indexed citations
20.
Buzzai, Monica, Russell G. Jones, Ravi K. Amaravadi, et al.. (2007). Systemic Treatment with the Antidiabetic Drug Metformin Selectively Impairs p53-Deficient Tumor Cell Growth. Cancer Research. 67(14). 6745–6752. 756 indexed citations breakdown →

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Kevin M. Ryan Breakdown of academic impact, for papers by Robert S. DiPaola Breakdown of academic impact, for papers by Domenico Coppola Breakdown of academic impact, for papers by Kapil N. Bhalla Breakdown of academic impact, for papers by Charles Dumontet Breakdown of academic impact, for papers by Hongming Pan Breakdown of academic impact, for papers by Ashok K. Saluja Breakdown of academic impact, for papers by Sergei I. Grivennikov Breakdown of academic impact, for papers by Satoru Todo Breakdown of academic impact, for papers by Galina K. Sukhova
Rankless by CCL
2026